1. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. (July 2015) Authors: Camaj, Peter; Primo, Stefano; Wang, Yan; Heinemann, Volker; Zhao, Yue; Laubender, Ruediger Paul; Stintzing, Sebastian; Giessen-Jung, Clemens; Jung, Andreas; Gamba, Sebastian; Bruns, Christiane Josephine; Modest, Dominik Paul Journal: Future oncology Issue: Volume 11:Number 13(2015) Page Start: 1919 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗